How should we respond to the highly toxogenic NAP1/ribotype 027 strain of Clostridium difficile?
Louie
Thomas J
TJ
Infectious Diseases Division, Department of Medicine, University of Calgary, Alta.
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D016360:Clostridioides difficile / Q000472:pathogenicity*; D003428:Cross Infection; D004196:Disease Outbreaks; D004761:Enterocolitis, Pseudomembranous; D006801:Humans; D017053:Infection Control; D054328:Proton Pump Inhibitors; D021521:Ribotyping; D012307:Risk Factors
D000900:Anti-Bacterial Agents; D054328:Proton Pump Inhibitors